Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $64.34 USD
Change Today -1.99 / -3.00%
Volume 2.7M
AZN On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 8:04 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc-spons adr (AZN) Key Developments

AstraZeneca Announces Executive Changes

AstraZeneca announced the departure of its respiratory and inflammatory medicines head James Ward-Lilley to become chief executive of Vectura. His departure follows the exit earlier June 2015 of Briggs Morrison, the company's former chief medical officer and head of latestage drug development, who moved on to become CEO of Syndax.

AstraZeneca Launches Research and Development Respiratory Centre in Spain and Plans to Invest USD 613 Million in R&D to Extend Respiratory Portfolio

AstraZeneca has launched a research and development (R&D) respiratory centre in the Spanish city of Barcelona. AstraZeneca plans to invest EUR 540 million (USD 613 million) during the next three years in R&D to extend its respiratory portfolio. This new R&D centre and the future investment in it will be for developing former Almirall respiratory portfolio - mainly, the production of leading respiratory products Eklira (aclidinium) and Duaklir Genuair (aclidinium + formoterol fumarate dihydrate). Additionally, AstraZeneca plans to continue with the clinical development of some promising treatments began by Alrmirall, such as once-daily, long-acting beta2-agonist (LABA) AS100977 (abediterol) currently undergoing Phase II development, and an M3 antagonist beta2-agonist (MABA) platform - comprising LAS191351, LAS194871, in pre-clinical development, and LAS190792, in Phase I development.

Roche And Johnson & Johnson Eyes Stake In GlaxoSmith

Swiss-based Roche Holding AG (SWX:ROG) and U.S.-based Johnson & Johnson are eying the U.K. company for approximately $143 billion. Moreover, there is also a rumor that Pfizer Limited (BSE:500680) was considering acquiring GlaxoSmithKline plc (LSE:GSK) a year after it failed to acquire AstraZeneca PLC. As per the poll conducted by BioSpace, AstraZeneca PLC could also be in the race to acquire struggling GlaxoSmithKline.

Roche, Pfizer, Johnson & Johnson And AstraZeneca In Race To Acquirer GlaxoSmithKline

Roche Holding AG (SWX:ROG) and Johnson & Johnson (NYSE:JNJ) are looking to buy GlaxoSmithKline plc (LSE:GSK) ('Glaxo') for approximately $143 billion. There is rumor that Pfizer Limited (BSE:500680) may also be considering acquiring Glaxo. As per the poll conducted by BioSpace, AstraZeneca plc (LSE:AZN) could also be in the race to acquire struggling GlaxoSmithKline.

AstraZeneca plc Announces Results from Type 2 Diabetes Analysis

AstraZeneca plc has announced results from an observational, retrospective analysis which found no evidence of increased risk of hospitalization for heart failure, or hHF, with saxagliptin, compared with sitagliptin, both of which are dipeptidyl peptidase-4, or DPP-4, inhibitors, in patients with type 2 diabetes. A similar finding was obtained when comparing the overall DPP-4 class to sulfonylureas. The analysis included patients with and without prior cardiovascular disease (CVD), and among those patients without prior cardiovascular disease (CVD), DPP-4 treatment was associated with statistically significant lower risk for hHF compared to treatment with sulfonylureas. These new data provide valuable real-world information regarding the cardiovascular safety of the DPP-4 inhibitor class in patients with type 2 diabetes.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:US $64.34 USD -1.99

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.01 USD -0.96
BASF SE €79.84 EUR +0.21
Celgene Corp $114.91 USD -3.01
Eli Lilly & Co $83.78 USD -2.07
Valeant Pharmaceuticals International Inc C$272.86 CAD -9.34
View Industry Companies
 

Industry Analysis

AZN

Industry Average

Valuation AZN Industry Range
Price/Earnings 65.3x
Price/Sales 3.2x
Price/Book 4.9x
Price/Cash Flow 65.3x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC-SPONS ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.